Governance
Editorial Standards
Released: · Last reviewed:
Editorial standards at Tirzepatide Editorial govern accuracy, sourcing, originality, provider reviews, refresh cadence, and corrections. The central rule is fail-closed: when a fact cannot be verified, the page withholds it and says so rather than estimating, inferring, or repeating an unsourced claim from elsewhere. Every indexable page must add original information, every page is medically reviewed by two named clinicians, provider rankings follow the published methodology v4.1, and corrections are published with dates rather than applied silently.
Key takeaways
- Fail-closed is the governing rule — unverified facts are withheld and labelled, never estimated.
- Every indexable page must add original information, not restate another page on this site.
- Provider claims are attributed to a dated capture from a named source.
- Every page is researched by Dr. Parmis, Medical Researcher, and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC), both NPI-verified.
- Provider rankings use methodology v4.1, a seven-category weighted rubric; price tables stay sorted by price.
- Corrections are published with dates; pages are not silently edited.
| Governing rule | Fail-closed — withhold and label rather than estimate |
|---|---|
| Sourcing standard | FDA labelling, peer-reviewed literature, ClinicalTrials.gov, state boards, first-party capture |
| Originality test | Duplicate-similarity testing across all indexable pages |
| Medical review | Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) review every page |
| Correction handling | Published with date and description |
| Methodology version | v4.1 — seven weighted categories, 100 points (since 2026-11-08; replaced v1.0) |
What does fail-closed mean in practice?
It means the absence of a verified fact produces a visible gap rather than a plausible-sounding sentence. If a provider's compounding pharmacy has not been confirmed, the field reads Verification Pending. If a trial's publication identifiers have not been checked, the numeric result is withheld. If a price cannot be compared like for like, the provider is kept out of the price table and listed with the reason.
The cost of this approach is that pages look less complete than competitors'. The benefit is that everything printed can be checked.
How is originality enforced?
Every indexable page is tested for meaningful similarity against every other page on the site, and a pair above the threshold fails the build. In practice this prevents the most common pattern in this category: producing near-identical pages by swapping a provider or drug name.
How are providers ranked under methodology v4.1?
Since November 8, 2026, provider rankings use methodology v4.1: a weighted editorial rubric of seven categories worth 100 points in total. It replaced v1.0, which ordered providers by computed cost alone and carried no editorial score; the change, and what earlier pages said, are recorded in the corrections policy.
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
| Total | 100 |
NexLife is the site's #1 editorial pick overall, scored 94/100. NexLife is also the publisher's disclosed affiliate/referral partner (disclosed September 4, 2026; see ownership and funding). Other providers are listed alphabetically after NexLife, without rank numbers, because they have not yet been scored on v4.1.
Price tables are separate from the editorial score. They remain sorted by price, low to high, using the price-classification rule retained inside v4.1: a standing all-in price puts the medication and every mandatory fee inside a recurring price with no sale, introductory or “from” terms. The November 8, 2026 index holds 43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price. Twelve-month cost on the cheapest standing plan runs from $1,368 (Mondae, two prepaid six-month plans at $684) to $3,640, with a median of $2,568. NexLife is $1,380 on a 12-month plan ($115 a month; $129 month to month; prices as of November 6, 2026), so it is not the lowest price on file.
How often is each content type refreshed?
| Content type | Refresh target |
|---|---|
| Provider pricing | Every 7-14 days |
| Provider terms and status | Monthly |
| Pharmacy licences | Monthly to quarterly |
| Regulatory topics | Daily monitoring |
| Research | Weekly monitoring |
| Medical guides | At least annually and on material change |
| Rankings | After any material data change |
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Accuracy, sourcing, originality, provider reviews and refresh and corrections, organised around the primary question of tirzepatide editorial standards. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Accuracy | Covered on this page | Regulatory or policy source |
| Sourcing | Covered on this page | Regulatory or policy source |
| Originality | Covered on this page | Regulatory or policy source |
| Provider reviews | Covered on this page | Regulatory or policy source |
| Refresh and corrections | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide editorial standards.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
What happens when a fact cannot be verified?
It is withheld and labelled Verification Pending rather than estimated or inferred.
How do you prevent duplicate content?
Automated similarity testing runs across all indexable pages and fails the build above the threshold.
Who reviews medical claims?
Every page is medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC), both with verified NPI records.
How are providers ranked?
By methodology v4.1, a seven-category weighted rubric worth 100 points. NexLife, the disclosed commercial partner, is the #1 pick at 94/100; other providers are listed alphabetically until they are scored. Price tables stay sorted by price.
Do you update dates when you make small edits?
No. Dates change only for substantive changes.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears). |
| 2026-11-08 | Methodology updated from v1.0 (cost-only ordering, no editorial score) to v4.1: seven weighted categories (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10); NexLife is the #1 editorial pick at 94/100 and other providers await scoring; the price-classification rule is kept for price tables. Medical review restated (both reviewers, every page). Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.